Suelane Ouro, MD
Interventional Pain Medicine · New York, NYNPI 1114908845
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $40,854 of the $67,560 with a category attached, or 60.5%. 59 manufacturers reported payments, led by Medtronic at 47.5% of the total. Reporting peaked in 2022 at $19,390 and has fallen 62.3% since, to $7,315 in 2025. Among interventional pain medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,236 payments — averaging $54.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$32K
- Boston Scientific$10K
- MML US, Inc.$5K
- Amgen$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Merz North America, Inc.$2K
- plus $14K from 53 others
Across 2 payments — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$2K
What the payments were for
- Consulting fees$1,6002%
- Speaking & faculty fees$20,92031%
- Grants$1920%
- Travel & lodging$3,9946%
- Food & beverage$40,85460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$13,118
- SYNCHROMED$5,450
- GENERAL PAIN MANAGEMENT$3,941
- ReActiv8$3,584
- INTELLIS$3,464
- INTELLIS ADAPTIVESTIM$1,933
- WaveWriter Alpha Prime 16$1,909
- VANTA ADAPTIVESTIM$1,803
- XEOMIN$1,767
- Prometra II$1,713
- Intracept$1,668
- Senza Spinal Cord Stimulation System$1,188
- SPECTRA WAVEWRITER$807
- GENERAL - THERAPIES$800
- RELISTOR$367
- INCEPTIV$291
- Evoke$281
- NEUROSTAR TMS THERAPY SYSTEM$278
- Vanta$271
- Neuromodulation Dspsbls and Accs$265
How this compares
$67,560 in reported general payments places this provider in the 95th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 24 | $63,216 |
| OxycontinOxycodone Hcl | 50 | $63,096 |
| RoxybondOxycodone Hcl | 25 | $48,018 |
| BelbucaBuprenorphine Hcl | 26 | $19,812 |
| UbrelvyUbrogepant | 15 | $15,999 |
| Xtampza ErOxycodone Myristate | 19 | $13,816 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 163 | $11,072 |
| Nucynta ErTapentadol Hcl | 11 | $8,782 |
| Oxycodone Hcl | 387 | $8,588 |
| LinzessLinaclotide | 12 | $7,601 |
| Morphine Sulfate ErMorphine Sulfate | 113 | $6,755 |
| Diclofenac Potassium | 39 | $5,628 |
| Diclofenac Sodium | 15 | $5,620 |
| MovantikNaloxegol Oxalate | 11 | $4,369 |
| Fentanyl | 50 | $4,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,284 | $63,21624 claims |
| Protega Pharmaceutials IncRoxybond | $327 | $48,01825 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er | $1,441 | $42,41156 claims |
| AbbVieUbrelvy, Linzess | $1,435 | $23,60027 claims |
| Redhill Biopharma Inc.Movantik | $90 | $4,36911 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $68 | $2,940113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in New York
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Kimberly SackheimNew York$102K
- Gerard DegregorisNew York$49K
- Marco PappagalloNew York$36K
- Jason SieffermanNew York$29K
- Barthelemy LiabaudNew York$20K
- Devi NampiaparampilNew York$18K
- Jeffrey DeygooNew York$11K
- Imran PunekarNew York$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.